Gottsmann M, Landgraf R, Londong W, Werder K
Klin Wochenschr. 1975 Dec 15;53(24):1161-6. doi: 10.1007/BF01476456.
Oral glucose tolerance tests (OGTT) were performed for two subsequent days in 4 patients with active acromegaly, 2 patients with prolactin-producing pituitary adenomas and one insulinoma patient. Thirty minutes before the second OGTT 250 mug of somatostatin were injected intravenously as a bolus followed by a somatostatin infusion (500 mug) over 21/2 hours. The OGTTs were pathologic due to the hGH- and hPRL-induced insulin antagonism; they could not be normalized or improved by somatostatin. Only the peak of the blood sugar curve was shifted from one to two and a half hours after glucose administration; insulin and hGH levels were regularly suppressed after somatostatin whereas hPRL remained unchanged in most instances. Gastrin levels increased in all patients during the OGTT, the increase was suppressed in 4 patients. These findings show that the pathologic glucose tolerance due to insulin antagonism could not be improved by somatostatin in contrast to the deteriorated glucose tolerance in insulinopenic states.
对4例活动性肢端肥大症患者、2例分泌催乳素的垂体腺瘤患者和1例胰岛素瘤患者连续两天进行口服葡萄糖耐量试验(OGTT)。在第二次OGTT前30分钟,静脉推注250微克生长抑素,随后在2.5小时内输注生长抑素(500微克)。由于hGH和hPRL诱导的胰岛素拮抗作用,OGTT结果异常;生长抑素不能使其恢复正常或改善。仅血糖曲线峰值从葡萄糖给药后1小时推迟至2.5小时;生长抑素给药后胰岛素和hGH水平通常受到抑制,而大多数情况下hPRL保持不变。OGTT期间所有患者胃泌素水平均升高,4例患者升高受到抑制。这些发现表明,与胰岛素缺乏状态下葡萄糖耐量恶化相反,生长抑素不能改善胰岛素拮抗引起的病理性葡萄糖耐量。